TRDA vs. VERA, AMRX, RCKT, CPRX, GLPG, AGIO, PTGX, ZLAB, KROS, and GPCR
Should you be buying Entrada Therapeutics stock or one of its competitors? The main competitors of Entrada Therapeutics include Vera Therapeutics (VERA), Amneal Pharmaceuticals (AMRX), Rocket Pharmaceuticals (RCKT), Catalyst Pharmaceuticals (CPRX), Galapagos (GLPG), Agios Pharmaceuticals (AGIO), Protagonist Therapeutics (PTGX), Zai Lab (ZLAB), Keros Therapeutics (KROS), and Structure Therapeutics (GPCR). These companies are all part of the "pharmaceutical preparations" industry.
Entrada Therapeutics (NASDAQ:TRDA) and Vera Therapeutics (NASDAQ:VERA) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.
Entrada Therapeutics currently has a consensus price target of $21.00, suggesting a potential upside of 35.75%. Vera Therapeutics has a consensus price target of $42.86, suggesting a potential upside of 12.81%. Given Entrada Therapeutics' higher probable upside, analysts clearly believe Entrada Therapeutics is more favorable than Vera Therapeutics.
Entrada Therapeutics has higher revenue and earnings than Vera Therapeutics. Vera Therapeutics is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Vera Therapeutics had 6 more articles in the media than Entrada Therapeutics. MarketBeat recorded 8 mentions for Vera Therapeutics and 2 mentions for Entrada Therapeutics. Entrada Therapeutics' average media sentiment score of 0.93 beat Vera Therapeutics' score of 0.70 indicating that Entrada Therapeutics is being referred to more favorably in the media.
Entrada Therapeutics has a beta of -0.38, suggesting that its stock price is 138% less volatile than the S&P 500. Comparatively, Vera Therapeutics has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500.
86.4% of Entrada Therapeutics shares are owned by institutional investors. Comparatively, 99.2% of Vera Therapeutics shares are owned by institutional investors. 7.6% of Entrada Therapeutics shares are owned by insiders. Comparatively, 21.7% of Vera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Vera Therapeutics received 14 more outperform votes than Entrada Therapeutics when rated by MarketBeat users. However, 73.33% of users gave Entrada Therapeutics an outperform vote while only 55.56% of users gave Vera Therapeutics an outperform vote.
Entrada Therapeutics has a net margin of 14.42% compared to Vera Therapeutics' net margin of 0.00%. Entrada Therapeutics' return on equity of 9.73% beat Vera Therapeutics' return on equity.
Summary
Entrada Therapeutics beats Vera Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Entrada Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TRDA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TRDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Entrada Therapeutics Competitors List
Related Companies and Tools
